RxDoctor Payments Data

Taralyn Johnson, PA

Physician Assistant · Laguna Hills, CANPI 1730784745

Payments from drug & device makers

$4,411in general payments, 2019–2025

Across 139 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Procept Biorobotics Corporation$482
  • Sumitomo Pharma America, Inc.$342
  • Antares Pharma, Inc.$299
  • Myriad Genetic Laboratories, Inc.$211
  • Johnson & Johnson$190
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$78518%
  • Food & beverage$3,59581%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,411 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$47,298
Medicare patients
251
Services billed
1,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron43$45,048
GemtesaVibegron27$20,909
Estradiol104$5,583
Tamsulosin Hcl291$5,498
Methenamine Hippurate31$2,991
Testosterone Cypionate43$2,598
Trospium Chloride46$2,558
Testosterone23$2,244
Oxybutynin Chloride ErOxybutynin Chloride29$1,184
YuvafemEstradiol14$1,167
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst99$1,081
Solifenacin Succinate20$889
Tadalafil26$808
Silodosin15$793
Ciprofloxacin Hcl121$714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$34$45,04843 claims
Sumitomo Pharma America, Inc.Gemtesa$342$20,90927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →